Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for brca genetic counseling referral

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 4, 2013, Pages 728-735

  Bellcross, Cecelia A ^a   Leadbetter, Steven ^b   Alford, Sharon Hensley ^c   Peipins, Lucy A ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CAUCASIAN; EDUCATIONAL STATUS; FAMILY HISTORY; FEMALE; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL; SOCIAL STATUS;

ADULT; ADVISORY COMMITTEES; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; DELIVERY OF HEALTH CARE; FEMALE; FOLLOW-UP STUDIES; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROGNOSIS; REFERRAL AND CONSULTATION; RISK FACTORS; UNITED STATES;

EID: 84876562670     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1280     Document Type: Article

References (40)

1. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000;83:1301-8.
2. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-706. (Pubitemid 44942707)
3. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 andBRCA2mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16. (Pubitemid 41798292)
4. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services USPSTF. Ann Intern Med 2005;143:362-79.
5. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33. (Pubitemid 46706879)
6. Isern AE, Loman N, Malina J, Olsson H, Ringberg A. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer. Eur J Surg Oncol 2008;34:1148-54.
7. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-7.
8. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-7.
9. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Issacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-75.
10. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. (Pubitemid 46535708)
11. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010;28:222-31.
12. Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011;29:1664-9.
13. Kaas R, Verhoef S, Wesseling J, Rookus MA, OldenburgHS, eeters MJ, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg 2010;251: 488-92.
14. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Issacs C, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-9. (Pubitemid 43286452)
15. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high-risk for breast cancer. Ann Intern Med 2008;148: 671-9. (Pubitemid 351669112)
16. United States Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143: 355-61.
17. Levy DE, Garber JE, Shields AE. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med 2009;24:822-8.
18. Hall IJ MA, Coughlin SS. Population prevalence of first-degree family history of breast and ovarian cancer in the United States: Implications for genetic testing. Open Health Serv Policy J 2008;1:38-44.
19. Palomaki GE, McClain MR, Steinort K, Sifri R, LoPresti L, Haddow JE. Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women. Genet Med 2006;8:161-8.
20. McClain MR, Palomaki GE, Hampel H, Westman JA, Haddow JE. Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women. Fam Cancer 2008;7:341-5.
21. Healthy People 2020: Genomics Objectives; 2011 [accessed 2011 Nov 13]. Available from: http://www.healthypeople.gov/2020/topicsobjectives2020/overview. aspx?topicId1/415.
22. Johnson JD, Case DO, Andrews JE, Allard SL. Genomics-the perfect information-seeking research problem. J Health Commun 2005;10: 323-9. (Pubitemid 40980948)
23. Percich S, Biro K, Hensley Alford S, Decker A, Trepanier A, Duquette D, et al. Surveillance of BRCA1/2 genetic testing referral and use. Abstract presented at the American College of Medical Genetics Annual Meeting 2010[Accessed2012Nov 1]. Available from: http://acmg.omnibooksonline. com/2010/index.html.
24. Research Triangle Institute. SUDAAN [computer program]; 2009. Research Triangle Park, NC.
25. Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 2011;40:61-6.
26. Trivers KF, Baldwin LM, Miller JW, Matthews B, Andrilla CH, Lishner DM, et al. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer 2011;117:5334-43.
27. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010;12: 245-59.
28. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian; 2011 [Accessed 2011 Dec 1]. Available from: http://www.nccn.org/professionals/ physician-gls/pdf/genetics-screening.pdf.
29. Breast and ovarian cancer and increased risk family history patterns. Genomics and Health; 2011 [Accessed 2011 Nov 13]. Available from: http://www.cdc.gov/genomics/resources/diseases/breast-ovarian-cancer/ history-patterns.htm.
30. Steiner E, Klubert D, Knutson D. Assessing breast cancer risk in women. Am Fam Phys 2008;78:1361-6.
31. Irshad S, Ashworth A, Tutt A. Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Rev Anticancer Ther 2011;11: 1243-51.
32. ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome. Gynecol Oncol 2009;113:6-11.
33. Katapodi MC, Lee KA, Facione NC, Dodd MJ. Predictors of perceived breast cancer risk and the relation between perceived risk and breast cancer screening: a meta-analytic review. Prev Med 2004; 38:388-402. (Pubitemid 38327011)
34. Dancyger C, Wiseman M, Jacobs C, Smith JA, Wallace M, Michie S. Communicating BRCA1/2 genetic test results within the family: a qualitative analysis. Psychol Health 2011;26:1018-35.
35. Kenen R, Arden-Jones A, Eeles R. We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC). Psychooncology 2004;13:335-45. (Pubitemid 38714195)
36. Koehly LM, Peters JA, Kenen R, Hoskins LM, Ersig AL, Kuhn NR, et al. Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. Am J Public Health 2009;99:2203-9.
37. Mai PL, Garceau AO, Graubard BI, Dunn M, McNeel TS, Gonsalves L, et al. Confirmation of family cancer history reported in a populationbased survey. J Natl Cancer Inst 2011;103:788-97.
38. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004;292:1480-9. (Pubitemid 39258342)
39. Ziogas A, Anton-Culver H. Validation of family history data in cancer family registries. Am J Prev Med 2003;24:190-8. (Pubitemid 36144098)
40. Cancer survivors-United States, 2007.MMWRMorb Mortal Wkly Rep 2011;60:269-72